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Abstract
 
Expression of the pre-B cell receptor (pre-BCR) leads to activation of the adaptor molecule
SLP-65 and the cytoplasmic kinase Btk. Mice deficient for one of these signaling proteins have
 
an incomplete block in B cell development at the stage of large cycling pre-BCR
 
 
 
CD43
 
 
 
 pre-B
cells. Our recent findings of defective SLP-65 expression in 
 
 
 
50% of childhood pre-B acute
lymphoblastic leukemias and spontaneous pre-B cell lymphoma development in SLP-65
 
 
 
/
 
 
 
mice demonstrate that SLP-65 acts as a tumor suppressor. To investigate cooperation between
Btk and SLP-65, we characterized the pre-B cell compartment in single and double mutant
mice, and found that the two proteins have a synergistic role in the developmental progression
of large cycling into small resting pre-B cells. We show that Btk/SLP-65 double mutant mice
have a dramatically increased pre-B cell tumor incidence (
 
 
 
75% at 16 wk of age), as compared
with SLP-65 single deficient mice (
 
 
 
10%). These findings demonstrate that Btk cooperates
with SLP-65 as a tumor suppressor in pre-B cells. Furthermore, transgenic low-level expression
of a constitutive active form of Btk, the E41K-Y223F mutant, prevented tumor formation in
Btk/SLP-65 double mutant mice, indicating that constitutive active Btk can substitute for
SLP-65 as a tumor suppressor.
Key words: Btk • lymphoma • precursor-B cell • SLP-65/BLNK • tumor suppressor
 
Introduction
 
B lymphocytes develop in the BM through distinct stages
that are characterized by differential expression of various
cell surface markers and the ordered rearrangement of Ig
heavy (H) and light (L) chain gene segments (1, 2). In pro-
B cells, productive V(D)J recombination of the Ig H chain
gene leads to surface expression of the pre-B cell receptor
(pre-BCR),
 
*
 
 which acts as a checkpoint in early B cell de-
velopment to monitor the expression of a functional Ig 
 
 
 
H chain. The pre-BCR is transiently expressed on the cell
surface and is essential for the proliferative expansion of cy-
toplasmic 
 
 
 
 H chain positive pre-B cells and for the induc-
tion of developmental progression into small pre-B cells in
which Ig L chain rearrangement occurs (1, 2). The pre-
BCR complex is comprised of 
 
 
 
 H chain, the nonrear-
ranging VpreB and 
 
 
 
5 surrogate light chain (SLC) proteins
and the Ig
 
 
 
/CD79a and Ig
 
 
 
/CD79b signaling compo-
nents. The importance of the pre-BCR checkpoint func-
tion is evidenced by an arrest of B cell differentiation at the
pro-B to pre-B cell transition both in agammaglobulinemia
patients and in mice with mutations in any of these pre-
BCR components (1–3).
Cell surface expression of the pre-BCR in the absence of
a ligand appears to be sufficient to activate downstream sig-
naling pathways (4, 5). This activation involves the forma-
tion of a lipid raft-associated calcium signaling module,
composed of the tyrosine phosphorylated signaling mole-
cules Lyn, Syk, SLP-65 (also known as B cell linker protein
BLNK or BASH), phosphoinositide 3-kinase (PI3K), Bru-
ton’s tyrosine kinase (Btk), Vav, and phospholipase C
 
 
 
2
(PLC
 
 
 
2). As a result, the activation of PLC
 
 
 
2 induces cal-
cium signaling and subsequently nuclear factor (NF)-
 
 
 
B
activation (6–8). Additional checkpoints follow when func-
tional L chain gene recombination in pre-B cells results in
the expression of the B cell receptor (BCR) and when the
resulting immature B cells progress to mature B cells. Mice
deficient for any of the (pre)-BCR signaling proteins ex-
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*
 
Abbreviations used in this paper:
 
 BCR, B cell receptor; Btk, Bruton’s ty-
rosine kinase; SLC, surrogate light chain.T
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hibit essentially similar immunological phenotypes, charac-
terized by reduced numbers of mature peripheral B cells,
absence of B-1 B cells, reduced levels of serum IgM and
IgG3, lack of in vivo responses to T cell–independent type
II antigens, and reduced in vitro responses to anti-IgM and
LPS stimulation (9).
Several lines of evidence show that the adaptor molecule
SLP-65 and the cytoplasmic kinase Btk are crucially involved
in the regulation of the developmental program of pre-B
cells, in particular by limiting pre-B cell expansion and pro-
moting differentiation of large cycling to small resting pre-B
cells. Both SLP-65–deficient and Btk-deficient mice show a
partial block at the pre-B cell stage, characterized by an im-
paired developmental progression from large cycling CD43
 
 
 
into small resting CD43
 
 
 
 pre-B cells (10–14). In an analysis
of the kinetics of pre-B cell differentiation in vivo, Btk-defi-
cient cells manifested a specific developmental delay within
the small pre-B cell compartment, when compared with
WT cells (14). By introduction of a transgenic BCR into
SLP-65-deficient mice, it was shown that in the absence of
SLP-65 the production of 
 
 
 
 light chain is decreased and cel-
lular maturation of developing B cell is delayed (15). Rein-
troduction of SLP-65 into SLP-65-deficient pre-B cells led
to pre-BCR down-regulation and enhanced differentiation
(16). Furthermore, SLP-65
 
 
 
/
 
 
 
 and Btk-deficient pre-B cells
show enhanced proliferative expansion in vitro in the pres-
ence of IL-7, when compared with WT cells (14, 16–17). A
synergistic role of SLP-65 and Btk in B cell development
was demonstrated by the almost complete block in B cell de-
velopment at the CD43
 
 
 
 pre-BCR
 
 
 
 preB cell stage in SLP-
65/Btk double mutant mice (18).
We recently reported that SLP-65
 
 
 
/
 
 
 
 mice spontane-
ously develop pre-B cell lymphomas expressing large
amounts of pre-BCR on their cell surface (16). Moreover,
also 
 
 
 
50% of human childhood preB acute lymphoblastic
leukemias (ALL) showed a complete loss or a drastic reduc-
tion of SLP-65 expression. Injection of murine SLP-65
 
 
 
/
 
 
 
pre-B cells into immunodeficient mice resulted in tumor
development, while reconstitution of SLP-65 expression in
these cells eliminated their tumorgenic capacity (19). Tyr
 
96
 
,
which is the binding site for Btk, was identified as a crucial
residue for the SLP-65 tumor suppressor function. Al-
though Btk-deficient mice do not develop pre-B cell tu-
mors, the possibility remains that Btk cooperates with
SLP-65 as a tumor suppressor in pre-B cells. To investigate
cooperation between Btk and SLP-65, we characterized
the pre-B cell compartment in single and double mutant
mice in detail. We show that Btk/SLP-65 double mutant
mice have a high incidence of pre-B cell lymphoma and
that transgenic expression of low levels of the constitutive
active E41K-Y223F Btk mutant prevents tumor formation
in SLP-65/Btk double mutant mice.
 
Materials and Methods
 
Mice.
 
Btk-deficient mice (20) were on the C57BL/6 back-
ground. Btk WT alleles were identified by an exon 9 forward
primer (5
 
 
 
-CACTGAAGCTGAGGACTCCATAG-3
 
 
 
) and an
 
exon 10 reverse primer (5
 
 
 
-GAGTCATGTGCTTGGAATAC-
CAC-3
 
 
 
). For Btk KO alleles, primers were within the LacZ
reporter (20), forward: 5
 
 
 
-TTCACTGGCCGTCGTTTTACA-
ACGTCGTGA-3
 
 
 
, and reverse: 5
 
 
 
-ATGTGAGCGAGTAAC-
AACCCGTCGGATTCT-3
 
 
 
. SLP-65-deficient mice (10) were
on the Balb/c background and genotyped with the following
primers: 
 
Neo2A
 
 5
 
 
 
-CGGAGAACCTGCGTGCAATC-3
 
 
 
 and
 
gxBr
 
 5
 
 
 
-GAGTCCGAATGTTCATCTG-3
 
 
 
 (KO allele) and
 
WtI
 
 5
 
 
 
-TCAAACCTGGGTCTCAGAA-3
 
 
 
 and 
 
gxBr
 
 (WT allele).
The presence of the Btk
 
Act
 
 transgene was evaluated by PCR, us-
ing the following primers: CD19prom: 5
 
 
 
-TGCAATTAGTG-
GTGAACAAC-3
 
 
 
 and hmBtk.65R: 5
 
 
 
-AGATGCCAGGACT-
TGGAAGG-3
 
 
 
.
The Btk
 
Act
 
 transgene consist of a 
 
 
 
6.3 kb genomic fragment
containing the CD19 promoter region, a 0.3 kb fragment with
the first three exons of human Btk as cDNA sequence, as well
as a 27.1 kb genomic DNA fragment, encompassing the Btk
exons 3–19 (21). Using double stranded site-directed mu-
tagenesis (Stratagene) the Y223F mutation, the replacement of
AT by TC in exon 8, was introduced into the construct that
was previously used to generate CD19-Btk
 
E41K
 
 mice. The 
 
 
 
34
kb MluI-NotI insert from the E41K-Y223F-Btk construct was
excised from the vector, gel-purified and micro-injected into
the pronuclei of FVB fertilized oocytes. Transgenic founder
mice were identified by Southern blotting of BamHI digests
using a partial human Btk cDNA probe (bp 133–1153), as de-
scribed previously (20, 21), and crossed with Btk null mice. All
mice were bred and maintained at the Erasmus MC animal
care facility under specific pathogen free conditions. Statistical
analyses of Kaplan-Meier tumor-free survival estimates of the
various mouse groups were performed using SPSS 10.1.0
(SPSS Inc.).
 
Cell Culture and Flow Cytometry.
 
IL-7 driven BM cultures
and determination of IL-7–dependent proliferative responses of
total BM cells have been described previously (14, 22). Prepara-
tions of single-cell suspensions, standard and intracellular flow cy-
tometry, and conjugated monoclonal antibodies (Becton Dickin-
son) have been described previously (14, 20). The anti-SLC
hybridoma LM34 (23) was kindly provided by A. Rolink (Uni-
versity of Basel, Basel, Switzerland); antibodies were purified us-
ing protein G columns and conjugated to biotin according to
standard procedures.
 
Western Blotting Analysis.
 
For analysis of Btk expression and
protein phosphorylation, single-cell suspensions from spleen were
depleted of erythrocytes by NH
 
4
 
Cl lysis and enriched for B cells
by AutoMACS purification, using biotinylated antibodies to
Gr-1, Ter119, CD4, CD8, and CD11b and magnetic streptavidin
MicroBeads (Miltenyi Biotec) for negative selection. B-lineage
cells were purified from BM by AutoMACS using anti-B220 Mi-
croBeads for positive selection. Splenic B cell fractions were stim-
ulated with 10 
 
 
 
g/ml F(ab
 
 
 
)
 
2
 
 fragment of polyclonal goat-
anti–mouse IgM (Jackson ImmunoResearch Laboratories) in
RPMI1640 at 37
 
 
 
C for 5 min. Western blotting was performed
as described (20), using anti-Btk C-20, anti-Erk1/2 SC-094
(Santa Cruz Biotechnology, Inc.), or anti-phosphotyrosine
P-Tyr-100 (Cell Signaling Technology).
 
Results and Discussion
 
Pre-B Cell Maturation Defects in Btk, SLP-65, and Double
Mutant Mice.
 
Btk or SLP-65 single mutant mice have a
partial block, while double mutant mice have an almostT
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complete arrest at the pre-B cell stage in the BM (10–14,
18). As a result, the reduction of the numbers of mature B
cells in the spleen of double mutant mice is much more
drastic, when compared with Btk or SLP-65 single mutant
mice (reference 18; Fig. 1 A). We have previously shown
that Btk-deficient cells fail to efficiently modulate the ex-
pression of developmentally regulated cell surface markers
during the transition of large cycling into small resting cy-
toplasmic 
 
 
 
 
 
 pre-B cells (14). In particular, in Btk-defi-
cient small pre-B cells the down-regulation of the pro-B/
large pre-B stage-specific markers SLC, the sialoglycopro-
tein CD43, and the metallopeptidase BP-1 and the up-reg-
ulation of CD2 and CD25/interleukin-2 receptor, which
are first expressed on small preB cells, are impaired (14). To
analyze the effect of SLP-65 inactivation or the concomi-
tant deficiency of SLP-65 and Btk on pre-B cell matura-
 
tion, we compared the expression of these developmentally
regulated markers in WT, Btk-deficient, SLP-65-deficient,
and double mutant mice by flow cytometry. As MHC class
II expression is also initiated at the pre-B cell stage (24), we
included surface expression of MHC class II of cytoplasmic
 
 
 
 
 
 pre-B cells in the analyses.
When compared with Btk-deficient cells, SLP-65
 
 
 
/
 
 
 
pre-B cells manifested a slightly more pronounced defect in
the down-regulation of CD43, BP-1, and SLC and in the
up-regulation of CD25, CD2, and MHC class II expres-
sion (Fig. 1 B). Consistent with the reported almost com-
plete arrest at the pre-BCR
 
 
 
 stage (18), SLP-65/Btk
double mutant pre-B cells had high forward scatter charac-
teristics, were positive for CD43, BP-1, and SLC expres-
sion and showed very low surface expression of CD25,
CD2, and MHCII (Fig. 1 B).
Collectively, these findings show that SLP-65 and Btk
have a synergistic role in the developmental progression of
large cycling into small resting cytoplasmic 
 
 
 
 
 
 pre-B cells.
 
Deficient Differentiation of Btk and SLP-65 Mutant Pre-B
Cells In Vitro.
 
Cytoplasmic 
 
 
 
 
 
 pre-B cells undergo rapid
cell division in response to IL-7 in vitro, whereby subse-
quent removal of IL-7 strongly induces exit from cell cycle
and further differentiation into surface IgM
 
 
 
 B cells (25).
We previously reported that Btk and SLP-65 single mutant
pre-B cells manifest an enhanced proliferative response to
IL-7 (14, 16). When we compared total BM cells from Btk
and SLP-65 single mutants and the double mutant, these
three groups of mice showed similar [
 
3
 
H]thymidine incor-
poration values after 5 d of culture in the presence of 100
U/ml IL-7 (Fig. 2 A). When total BM cell suspensions
from WT mice were cultured in the presence of IL-7 for 7
d, the majority of cells consisted of B220
 
 
 
 cytoplasmic 
 
 
 
 
 
pre-B cells that were surface 
 
 
 
 
 
 or 
 
 
 
low
 
, while a significant
fraction (
 
 
 
20–30%) performed productive 
 
 
 
 L chain
rearrangements and matured to surface IgM
 
 
 
IgD
 
 
 
 or
IgM
 
 
 
IgD
 
 
 
 B cell stages (Fig. 2 B, thin lines). In contrast,
the IL-7 driven BM cultures from Btk and SLP-65 single
or double mutant mice consisted almost exclusively of large
 
 
 
 
 
 SLC
 
 
 
 pre-B cells which did not express 
 
 
 
 L chains in
their cytoplasm (Fig. 2 B, thin lines).
To analyze the differentiation capacity of pre-B cells,
BM cells were cultured in the presence of IL-7 for 5 d
and subsequently for 2 d on S17 stroma cells in the ab-
sence of IL-7. Under these conditions, WT cells acquired
low FSC characteristics and 
 
 
 
50% of the cells showed
productive 
 
 
 
 L chain rearrangement and differentiated
into IgM
 
 
 
IgD
 
 
 
 cells. In contrast, the cultures from Btk-
deficient mice contained no IgD-positive cells, a smaller
fraction (
 
 
 
25%) of cytoplasmic 
 
 
 
 
 
 cells, and a significant
proportion of SLC
 
 
 
 cells. The defects were more pro-
nounced in the cultures from SLP-65
 
 
 
/
 
 
 
 and Btk/SLP-65
double mutant mice, which were characterized by an in-
efficient exit from cell cycle and a dominance of SLC
 
 
 
  
pre-B cells. In this respect, these two groups of mice were
not significantly different.
Only when BM cells were cultured in the presence of
limiting concentrations of IL-7 for 7 d, a difference be-
Figure 1. Impaired pre-B cell maturation in Btk-deficient, SLP-65-defi-
cient, and Btk/SLP-65 double mutant mice. (A) Flow cytometric analysis
of surface IgM/IgD expression on total lymphoid cells in the spleen. (B)
Expression profiles of B220 and IgM on total lymphoid cells in the BM
(top). The B220 IgM  pro-/pre-B cell fraction was gated and analyzed
for the indicated markers (bottom). Data are displayed as dot plots and the
percentages of cells within the indicated quadrants or gates are given. Data
shown are representative of four mice examined within each group.T
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tween SLP-65 single mutant and SLP-65/Btk double mu-
tant mice was noticed (Fig. 2 C). At low IL-7 concentra-
tions, preB cell division was limited and cells rapidly
differentiated into surface IgM  B cells. Within the popu-
lation of small noncycling B220  cells, the percentage of
surface IgM  cells was lower in SLP-65/Btk double mu-
tant mice, when compared with WT, Btk, or SLP-65 sin-
gle mutant mice. These results indicate that, in the absence
of SLP-65, Btk functions to enhance differentiation to
sIgM  B cells at low IL-7 concentrations.
Taken together, these findings show that in the presence
of IL-7 Btk, SLP-65, and double mutant pre-B cells show
increased proliferation and enhanced pre-BCR expression,
when compared with WT pre-B cells. The ability to
down-regulate SLC expression and to differentiate into
IgM  B cells upon IL-7 withdrawal, is mildly affected in
Btk-deficient mice, more severely in SLP-65 /  mice, and
even more so in SLP-65/Btk double mutant mice.
Btk/SLP-65 Double Mutant Mice Have a High Incidence of
Pre-B Cell Lymphoma. SLP-65 /  mice develop sponta-
neous pre-B cell tumors, with a frequency of  10% at 16
wk of age (16). When we followed a panel of SLP-65 sin-
gle mutant mice up to 16 wk,  5% (3 out of 66) devel-
oped a lymphoma. Remarkably, when SLP-65/Btk double
mutant mice were followed for 16 wk, a significantly en-
hanced frequency of tumor development was noticed, be-
cause 75% of these mice (12 out of 16) developed a pre-B
cell lymphoma. In these mice external examination re-
vealed either directly the presence of solid tumors, mainly
close to the scapula, or indirectly as the mice displayed
pareses of the hind limbs. In general, the mice also devel-
oped splenomegaly, and enlargement of the lymph nodes.
Comparable tumors were not found in WT or Btk-defi-
cient mice (less than 1/4,000 mice). The Kaplan-Meier tu-
mor-free survival curves for the SLP-65 single and SLP-
65/Btk double mutant mice are shown in Fig. 3 A.
These results demonstrate that deficiency of Btk strongly
increases the frequency of tumor formation in SLP-65 / 
mice, indicating that Btk cooperates with SLP-65 as a tu-
mor suppressor in preB cells.
Constitutive Active BtkAct Prevents Pre-B Cell Tumor Forma-
tion in Btk/SLP-65 Double Mutant Mice. The finding that
Btk apparently cooperated with SLP-65 as a tumor sup-
pressor prompted us to investigate whether transgenic ex-
pression of a constitutive active Btk mutant could prevent
tumor development in SLP-65-deficient mice. The PH
domain gain-of-function mutant E41K shows increased
membrane localization and phosphorylation in quiescent
cells, independent of PI3K activity and induces transfor-
mation of 3T3 fibroblasts in soft agar cultures (26, 27).
This capacity is augmented by mutation of the main auto-
phosphorylation site in the Btk SH3 domain (Y223F; ref-
erence 28). In Ramos B cells expression of E41K-Btk en-
hances the sustained increase in intracellular [Ca2 ] after
BCR cross-linking (29). Thus, the E41K mutant and the
E41K-Y223F double mutant represent activated forms of
Btk. When E41K-Btk was expressed at physiological levels
in transgenic mice under the control of the B cell–specific
CD19 promoter, B cell development was arrested at the
immature B cells in the BM (probably because the E41K-
Btk mutant mimics BCR occupancy by auto-antigens),
while residual B cells were efficiently driven into IgM
plasma cell differentiation (21). We recently generated a
panel of 7 independent E41K-Btk (n     3) or E41K-
Figure 2. Analysis of IL-7 driven BM cultures from
Btk and SLP-65 mutant mice. (A) Proliferative re-
sponse to 100 U/ml IL-7, as determined by [3H]thymi-
dine incorporation after 5 d of culture. Bars represent
mean cpm and SEM of triplicate cultures. (B) Forward
scatter (FSC) values and expression profiles of IgM,
IgD, SLC, and cytoplasmic   L chain of IL-7 driven
BM cultures from the indicated mice. Data are dis-
played as histogram overlays of B220  cells, either cul-
tured under proliferating conditions (with 100 U/ml
IL-7 for 7 d, thin lines) or under differentiating condi-
tions (after 5 d of culture with IL-7 and subsequently
without IL-7 for 2 d, bold lines). The percentages
shown represent the fractions of the cells that are
within the indicated marker under the two different
culture conditions. (C) Percentage of surface IgM 
cells within the fraction of small FSC B220  cells after
7 d of culture in the presence of the indicated concen-
trations of IL-7. Data are representative of four mice
per group.T
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Y223F-Btk (n   4) transgenic mouse lines, which were
crossed onto the Btk null background. Expression of the
two different mutants resulted in parallel phenotypes,
whereby the deletion at the immature B cell stage was
dose-dependent (unpublished data). From this panel we
selected a low-copy E41K-Y223F-Btk transgenic mouse
strain (BtkAct), in which the extent of the B cell arrest was
limited, while the finding of enhanced protein tyrosine
phosphorylation in splenic B cells and significantly in-
creased serum IgM levels provided evidence for the con-
stitutive active nature of BtkAct in vivo (see below; Fig. 4,
A–C).
BtkAct mice were crossed onto the Btk/SLP-65 double
mutant background and a panel of 20 transgenic mice was
followed for 8 mo. At this age, the fraction of SLP-65 / 
mice that developed a preB cell lymphoma increased to
18% (12 out of 66; Fig. 3 B). In contrast, none of the BtkAct
transgenic mice on the Btk/SLP-65 double mutant back-
ground developed lymphoma (Fig. 3 B). When these BtkAct
mice were killed at 8 mo, no evidence for ongoing pre-B
cell proliferation was found: pre-B cell numbers in the BM
were not increased and splenomegaly or pre-B cell infiltra-
tions into the spleen were absent.
These findings show that substitution of endogenous Btk
by low levels of constitutively activated Btk prevents tumor
formation in SLP-65–deficient mice. Therefore, we con-
clude that BtkAct can substitute for SLP-65 as a tumor sup-
pressor in pre-B cells.
Figure 3. (A) Kaplan-Meier tumor-free survival es-
timates for Btk-deficient (dotted line), SLP-65 /  (thin
line), and Btk-SLP-65 /  mice (bold line). Tumor-free
survival in Btk-SLP-65 /  mice was significantly re-
duced (P   0.0001 by log-rank) compared with SLP-
65 /  mice. (B) Kaplan-Meier tumor-free survival es-
timates for SLP-65 /  (thin line) and BtkActSLP-65 / 
mice (dotted line). Tumor-free survival in BtkActSLP-
65 /  mice was significantly enhanced (P   0.04 by
log-rank) compared with SLP-65 /  mice.
Figure 4. Low-level BtkAct expression can partially substitute for the absence of Btk and SLP-65. (A) Western blotting analysis of Btk expression in
WT and BtkAct B cells from BM and spleen. Membrane was reblotted with anti-Erk. (B) Protein tyrosine phosphorylation in extracts of untreated and
anti-IgM stimulated WT or BtkAct splenic B cells, analyzed by immunoblotting with a phosphotyrosine (pY)-specific antibody. Membrane was reblotted
with anti-Erk. (C) Serum concentrations of IgM and IgG3 in the indicated mutant mouse strains. Mice were 2 mo of ages and each symbol represents an
individual animal. (D) Flow cytometric analysis of surface IgM/IgD expression on total lymphoid cells in the spleen of the indicated mice. (E) Expression
profiles of B220 and IgM on total lymphoid cells in the BM of the indicated mice (top). The B220 IgM- pro-/pre-B cell fractions were gated and ana-
lyzed for CD43/FSC and cytoplasmic SLC and   H chain (bottom). Data are displayed as dot plots and the percentages of cells within the indicated
quadrants or gates are given. Data shown are representative of four mice examined within each group.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
96 Btk and SLP-65 Cooperate as Tumor Suppressors
Low Level BtkAct Expression Can Partially Substitute for the
Absence of Btk and SLP-65. BtkAct protein expression was
analyzed by Western blotting of purified B cell fractions
from BM and spleen, in which Btk protein was visible as a
single  77 kD band (Fig. 4 A). Quantification of Btk sig-
nals using Erk1/2 as a loading control showed that BtkAct
expression was low (up to  20% of the physiological lev-
els). This was confirmed in intracellular flow cytometry ex-
periments by comparison of median fluorescence intensities
of transgenic BtkAct and endogenous Btk (unpublished
data). The analysis of unstimulated and anti-IgM stimulated
splenic B cells by immunoblotting with a phosphotyrosine-
specific antibody revealed that BtkAct B cells exhibit en-
hanced protein tyrosine phosphorylation in vivo (Fig. 4 B).
To evaluate the capacity of BtkAct to drive peripheral B
cells into plasma cell differentiation, we determined serum
IgM and IgG3 levels in 2-mo-old BtkAct mice, both on a
Btk-deficient and on a Btk/SLP-65 double-deficient back-
ground, with nontransgenic WT, Btk , SLP-65 / , and
Btk/SLP-65 double-deficient mice as controls. Consistent
with previous reports, the serum levels of IgM and IgG3 in
mice deficient for Btk or SLP-65 were significantly de-
creased (10–12, 30). In Btk/SLP-65 double mutant mice
IgM levels equally low and IgG3 levels were even more re-
duced (Fig. 4 C). When BtkAct was expressed on the Btk-
deficient background, the levels of IgM in the serum were
increased with a factor of  5–10 and IgG3 levels were in
the normal range, when compared with WT mice. Also
the frequencies of IgM-producing cells in spleen and BM,
as determined in an ELISPOT assay, were increased in
these BtkAct mice (unpublished data). Expression of BtkAct
completely corrected IgM levels and significantly restored
IgG3 levels in Btk/SLP-65 double mutant mice (Fig. 4 C).
Flow cytometric analyses of the spleen revealed that
low-level expression of BtkAct did not rescue the decrease
in splenic B cell numbers in Btk-deficient mice (Fig. 4 D).
On the other hand, BtkAct expression also did not result in
significant deletion of peripheral B cells, in contrast to our
previous findings in mice expressing physiological levels of
the E41K-Btk mutant (21). Expression of BtkAct partially
restored the almost complete absence of splenic B cells in
Btk/SLP-65 double mutant mice, whereby their surface
IgM/IgD profiles were similar to those in SLP-65 single
mutant mice (see Figs. 1 A and 4 D). In the bone marrow,
expression of the BtkAct transgene corrected the maturation
defects of Btk-deficient c   pre-B cells, i.e., the down-
regulation of CD43 and SLC expression and the up-regula-
tion of CD2, CD25, and MHC class II expression (un-
published data; shown for CD43 and SLC in Fig. 4 E). In
SLP-65 /  mice, substitution of endogenous Btk by very
low levels of constitutively activated Btk was associated
with a reduction of the percentages of SLC  and CD43 
c   pre-B cells (Fig. 4 E).
Taken together, comparison of SLP-65 /  and BtkAct
SLP-65 /  mice with respect to serum Ig concentration
and the maturation of pre-B cells in vivo indicate that low-
level BtkAct expression can partially substitute for the ab-
sence of SLP-65.
Characterization of Pre-B Cell Tumors. All pre-B cell tu-
mors characterized expressed high levels of SLC and Ig  
H chain in their cytoplasm, irrespective of the Btk geno-
type of the SLP-65 /  mice (Fig. 5 A). The two Btk / 
SLP-65 /  mice present in our panel of mutant mice also
rapidly developed pre-B cell tumors. Because of the pres-
ence of a LacZ reporter in the targeted Btk allele, we could
evaluate the X-chromosome inactivation status of the lym-
phoma cells (20). As a result of the process of random X-chro-
mosome inactivation in Btk /  heterozygous females, each
X chromosome is active in about half of the pre-B cells. Simi-
lar to findings in lymphoma cells from male Btk SLP-65 / 
mice, we observed that the majority of lymphoma cells
from Btk / SLP-65 /  mice were LacZ . These results in-
dicate that the Btk /  lymphoma cells carried the disrupted
Btk allele on the active X chromosome and therefore were
functionally Btk-deficient (Fig. 5 B).
As both Btk and SLP-65 are crucially involved in the
modulation of pre-B cell surface makers and the initiation
of Ig L chain gene rearrangement during the transition of
large cycling into small resting cytoplasmic    pre-B cells,
Figure 5. Characterization of pre-B cell tumors by flow cytometry. (A)
Dot plots for cytoplasmic SLC and   H chain in gated B220  cells from
tumor samples from the indicated mice, grown for 1 to 3 wk in the pres-
ence of IL-7. (B) Flow cytometric analysis of lacZ expression in gated
CD19 B220  pre-B lymphoma cells in a lymph node from a Btk / SLP-
65 /  mouse. (C) Phenotype of two pre-B cell lymphoma cultures,
showing variable expression of cytoplasmic   L chain, CD43, and CD2.
Cell suspensions were stained for the indicated markers in combination
with B220, and the results are displayed as dot plots of gated B220  cells.
(D) Phenotype of two separate tumor cell suspensions derived from BM
and mesenteric lymph node from a single mouse, which were cultured in
the presence of Il-7 for 7 d.T
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we were interested in the phenotype of pre-B cell lym-
phoma cells. Most pre-B cell lymphomas contained a (mi-
nor) fraction of cells that coexpressed   L chain and SLC in
their cytoplasma and showed variable surface expression of
the developmentally regulated markers, such as CD43 and
CD2 (Fig. 5 C). In general, the expression of SLC and cell
surface markers remained stable when the tumor cells were
cultured in the presence of IL-7. Some of these cell lines
became IL-7 independent or lost expression of the IL-7R,
as detectable by flow cytometry (unpublished data). When
we cultured pre-B lymphoma cells derived from different
tissues from a single Btk/SLP-65 double mutant mouse in
vitro, we found that a BM-derived cell culture mainly con-
sisted of   L chain positive cells, while a lymph node–
derived cell culture was essentially   L chain negative.
Nevertheless, both cultures expressed high levels of CD43
and low levels of CD2 (Fig. 5 D).
Collectively, these results show that in the tumors the or-
dered differential expression of stage-specific pre-B cell
markers (CD43, SLC, and BP-1 on large cycling pre-B cells
but CD2, CD25, and MHCII on small resting pre-B cells)
is lost. Furthermore, the finding of variable percentages of  
L chain expressing cells in the pre-B cell lymphomas sug-
gests that in the absence of SLP-65 Ig L chain locus rear-
rangements are initiated in large cycling pre-BCR  cells.
Btk and SLP-65 Cooperate as Tumor Suppressors. By
crossing SLP-65 /  mice with mice that were either Btk-
deficient or expressed a constitutive active form of Btk we
have demonstrated in this report that (a) Btk and SLP-65
have synergistic roles in the developmental progression of
large cycling into small resting pre-B cells, (b) the concom-
itant deficiency of Btk significantly enhanced tumor forma-
tion in SLP-65 /  mice, and (c) expression of BtkAct pre-
vents tumor formation in Btk/SLP-65 double mutant
mice. We therefore conclude that BtkAct compensates for
loss of SLP-65 tumor suppressor function, either by pro-
moting pre-B cell differentiation or limiting pre-B cell ex-
pansion independent of SLP-65.
In contrast to SLP-65 /  mice, Btk/SLP-65 double mu-
tant mice exhibit an almost complete arrest at the large cy-
cling pre-BCR  pre-B cell stage. Thus, it is conceivable
that the increased frequency of malignant transformation in
Btk/SLP-65 double mutant mice reflects the increased
pool size of proliferating pre-B cells with a reduced ability
to progress into CD43  small resting pre-B cells, when
compared with SLP-65 single mutant mice. Alternatively,
the absence of Btk may alter the proliferative capacities of
SLP-65 /  pre-B cells in a signaling pathway different
from the pre-BCR. In this respect, the IL-7R pathway
would be an attractive candidate, as Btk-deficient RAG-
1 /  pro-B cells were shown to have an increased respon-
siveness to IL-7, when compared with Btk  RAG-1 / 
pro-B cells (14). A third possibility would be that the con-
comitant absence of Btk and SLP-65 precludes the efficient
down-regulation of RAG enzyme levels upon pre-BCR
signaling (1, 2). The finding of SLC and   L chain coex-
pression in the pre-B cell tumors suggests that Ig L chain
rearrangements have occurred in large pre-BCR  cycling
pre-B cells. This implies that the V(D)J recombination ma-
chinery is active in SLP-65 /  cycling pre-B cells, which
may cause DNA damage contributing to the induction of
secondary mutations required for malignant transformation.
Further experiments comparing Btk  and Btk  SLP-65-
deficient preB cell tumor cells should identify the nature of
the cooperation between Btk and SLP-65 as tumor sup-
pressors. In this context, we found that Btk expression lev-
els vary considerably between different pre-B cell lines es-
tablished from SLP-65 /  mice. Btk was not detectable in
1 out of 6 SLP-65 /  pre-B cell lines by Western blotting,
suggesting that Btk could be a target for secondary muta-
tions in SLP-65 /  mice (unpublished data). As SLP-65 is
implicated in childhood pre-B ALL (19), the finding of co-
operation between Btk and SLP-65 may also have impor-
tant implications for our understanding of the etiology of
this malignancy in humans.
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